Vaderis Therapeutics’ goal to develop the first drug aimed specifically at a certain rare blood vessel disorder came one step closer today with the news that the therapy is safe and reduced nosebleeds.

Siemens Healthineers aims to grow its PET imaging business by picking up the radiodiagnostic manufacturing and distribution network of Novartis’ Advanced Accelerator Applications division.

Galapagos is coming under additional pressure from investors. Having built a 9.9% stake in Galapagos, EcoR1 Capital is now planning to talk to the Belgian biotech about its performance and the composition of its board.

After getting the green light from the FDA back in March, Dexcom today launched its first over-the-counter wearable continuous glucose biosensor, Stelo, in the U.S. market.

Procept BioRobotics shares soared 30% on Wednesday after the company said its robotic system designed to treat benign prostatic hyperplasia received clearance from the Food and Drug Administration (FDA).

Pythons are famous for swallowing enormous meals whole—including morsels bigger than their own body mass. In order to digest these infrequent feasts, the snake’s heart works overtime by increasing its oxygen use, pumping more blood and swelling in size. This rapid response requires a heart that is soft and flexible, the opposite of the stiff and fibrous heart that is characteristic of many human cardiac diseases.

Bicara Therapeutics and Zenas Biopharma have provided fresh impetus to the IPO market with filings that illustrate what newly public biotechs may look like in the back half of 2024.

Mechanical ventilation, the use of a machine to help a person breathe, was not something many people thought about all that often—until the COVID pandemic struck. Stories of patients being put on ventilators, along with associated shortages of these machines, were blasted across the news, thrusting this decades-old treatment into the spotlight.

Eli Lilly has expanded its partnership with Oblique Therapeutics, adding a second strand to an alliance focused on using the AbiProt platform to discover antibodies against high-value targets.

With just weeks to go before the FDA decides whether to approve the first treatment for a rare genetic condition, Rafael Holdings is merging with Cyclo Therapeutics to try to push their own candidate over the line.